Instant BioSensing Technologies, Inc.

IBT is created by a few scientists, engineers and senior managers that work together to develop an original solution, in the midst of the Coronavirus (Covid-19) pandemic, to deploy a fast and massive test solution. That solution, based on a non-invasive spectroscopic and AI approach, will allow a family of products, that will produce instantaneous test results (infected/not infected), from a large-scale industrial test system for large volume sequential testing at places like airports and stadiums, all the way to the development of a personal size device, connected to a smartphone at a price below the present cost of a single test. The identification of Asymptomatic cases, along with the ability to confirm that some individuals, in the early stage of the infection are actually infected, will allow the quick isolation of those cases away from the rest of the population, dramatically slowing the spread of the infection. Mission To provide, to all levels of society and in all countries of the world, a fast and effective Covid-19 test solution, as soon as possible. That development will then allow us to expand this technology to detect Covid-19 generated antibodies and other disease tests, such as cancer and others. Ultimately, IBT’s objective is to contribute to and lead the medical spectroscopic detection market worldwide.